Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Lenvatinib and Pembrolizumab in Mucosal Melanoma
NCT04622566Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and pembrolizumab in mucosal melanoma (MM), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Pathological Complete Response Rate at 10 weeks. Status: unknown.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT04622566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622566.